Achieving Durable Outcomes in Treatment-Naïve nAMD 

DISCLOSURE POLICY

It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.

Sunir J. Garg, MD, FACS, FASRS, has had a financial relationship or affiliation with the following ineligible companies in the form of Advisory Board: Coherus. Consultant: American Academy of Ophthalmology, Apellis, Archimedic, Bausch + Lomb, Boehringer Ingelheim, Carl Zeiss Meditec, Merck Manual, and West Pharmaceuticals. Grant/Research Support: American Academy of Ophthalmology, Apellis, Boehringer Ingelheim, Genentech, Kodiak Biosciences, NGM Bio, and Regeneron. Speaker's Bureau: Canadian Ophthalmological Society, Cole Eye Summit, Physicians' Education Resource, and Retina Fellows Forum.

Charles C. Wykoff, MD, PhD, FACS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: 4DMT, AbbVie, ADARx, Adverum Biotechnologies, Alcon, Alimera, Alkeus, Allgenesis, AMC Sciences, Annexon, Apellis Pharmaceuticals, Ascidian, Astellas, Aviceda, Bausch + Lomb, Bayer, Biocryst, Bionic Vision, Boehringer Ingelheim, Carl Zeiss Meditec, Chengdu Kanghong Biotechnology, Curacle, Emmecell, Eyebiotech, EyePoint Pharmaceuticals, Frontera, Genentech, InGel, Janssen, Kiora, Kodiak Sciences, Kowa, Nanoscope, Neurotech, NGM Biopharmaceuticals, Novartis, Oak Bay Bio, Ocular Therapeutix, OcuTerra, Ollin, ONL, Opthea, Opus, Osanni, Oxular, Palatin, Panther, PerceiveBio, Perfuse, PolyPhotonix, Ray, RecensMedical, Regeneron, Regenxbio, RetinAI, Roche, Samsung Bioepis, Sandoz, Sanofi, Santen, Skyline, Stealth, Suzhou Raymon, Sylentis, TCG Crossover, Thea Pharma, Therini, TissueGen, VH401, Vitranu, and Visgenx. Grant/Research Support: 4DMT, AbbVie, Adverum Biotechnologies, AffaMed, Alexion, Alimera Sciences, Allgenesis, Amgen, Annexin, Annexon, Apellis Pharmaceuticals, Ascidian, AsclepiX Therapeutics, Astellas, Aviceda, Avirmax, Bayer, Boehringer Ingelheim, Chengdu Kanghong Biotechnology, Clearside Biomedical, Curacle, Eluminex, EyeBiotech, EyePoint Pharmaceuticals, Genentech, IONIS, iRENIX, Janssen, Kalaris, Kodiak Sciences, Kyoto DDD, Kyowa Kirin, Nanoscope, Neurotech, NGM Biopharmaceuticals, Novartis, Ocugen, Ocular Therapeutix, Oculis, OcuTerra, OliX, Opthea, Outlook Therapeutics, Oxular, Oxurion, Oyster Point, PerceiveBio, Pykus, Regeneron, Regenxbio, Rezolute, Roche, Shanghai Henlius, Stealth, Skyline, and VH401. 

The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.